Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine And Low Dose TBI With Disease-Risk Based Immunosuppression

Next Previous
X
Search
Trial Profile

Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine And Low Dose TBI With Disease-Risk Based Immunosuppression

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludarabine (Primary) ; Ciclosporin; Ciclosporin; Mycophenolate mofetil; Mycophenolate mofetil
  • Indications Amyloidosis; Chronic lymphocytic leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 17 Jan 2020 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2012 Planned end date changed from 1 Dec 2003 to 1 Feb 2005 as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Planned end date (1 Dec 2003) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top